SCHEMBL6325753

SCHEMBL6325753

CCCOc1ccc(S(=O)(=O)N(C)CC(C)S)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.67
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA7 P43166 2/20 0.51
CA9 Q16790 2/20 0.51
MMP3 P08254 5/20 0.47
TSHR P16473 2/20 0.44
MMP2 P08253 3/20 0.44
MMP13 P45452 3/20 0.44
MMP8 P22894 2/20 0.44
MMP1 P03956 1/20 0.44
MMP9 P14780 1/20 0.44
MMP14 P50281 1/20 0.44
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
MMP7 P09237 1/20 0.43
GBA1 P04062 1/20 0.42
LMNA P02545 3/20 0.41
HTT P42858 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323360 0.92 ADAM17 (0.64) ADAM17CA12CA1CA2CA7
SCHEMBL6324867 0.89 ADAM17 (0.70) ADAM17CA12CA1CA2CA7
SCHEMBL6323461 0.86 CA12 (0.51) ADAM17CA12CA1CA2CA7
SCHEMBL6323224 0.82 ADAM17 (0.65) ADAM17MMP3TSHRMMP2MMP13
SCHEMBL6320959 0.79 ADAM17 (0.61) ADAM17MMP3MMP2MMP13MMP8
SCHEMBL19001352 0.79 CA12 (0.64) CA12CA1CA2CA7CA9
SCHEMBL6325750 0.78 CA12 (0.51) ADAM17CA12CA1CA2CA7
SCHEMBL6325747 0.78 CA12 (0.51) ADAM17CA12CA1CA2CA7
SCHEMBL6322271 0.77 MMP3 (0.59) ADAM17CA12CA1CA2CA7
SCHEMBL6323458 0.75 CA12 (0.51) ADAM17CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 ADAM17 27/4885CA12 248/4885CA1 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.